Jing Ji Guan Cha Wang·2025-12-30 13:15Company Dynamics - Zhou Zhiwen, a major shareholder and actual controller of Zhaoyan New Drug (603127.SH), has announced a significant share reduction plan, potentially cashing out over 500 million yuan based on the current stock price [2] - Before the reduction, Zhou held 74,725,981 shares, accounting for 9.9704% of the total share capital, with a combined holding of 32.274% with his spouse, Feng Yuxia [2] - Following the announcement of the share reduction, Zhaoyan New Drug's stock dropped by 6.20% on December 30, closing at 34.80 yuan, indicating a potential cash-out of over 500 million yuan from the sale of 14.98 million shares [2] Industry Insights - Zhaoyan New Drug specializes in non-clinical research services, clinical services, and the supply of experimental models, gaining prominence in the capital market due to its assets in experimental monkeys [2] - The average market price of experimental monkeys has seen significant fluctuations, with prices rising from 13,800 yuan per monkey in 2017 to nearly 190,000 yuan in 2022, before experiencing a decline in 2023 [2][3] - In November 2023, the price of experimental monkeys dropped to approximately 113,000 yuan each, reflecting a decrease of over 30% from the peak [3] - Despite a decline in revenue by 26.23% year-on-year to 985 million yuan in the first three quarters of 2025, Zhaoyan New Drug managed to achieve a net profit of 80.71 million yuan, indicating a recovery in performance [3] - As of December 29, 2025, Zhaoyan New Drug's stock price has increased by over 120% within the year [3] Shareholder Activity - Zhou Zhiwen has a history of share reductions, having sold a total of 14.11 million shares since November 2020, resulting in approximately 915 million yuan in cash [4]